Alvotech Shares Jump 13.5% After FDA Clears AVT02 Manufacturing Changes
Alvotech’s $ALVO shares jumped 13.5% after FDA approval of AVT02 manufacturing changes, sharpening the focus on supply and commercial scale-up.
GE HealthCare’s $945 Million Sofie Deal Signals Broader Radiopharmaceutical Push
GE HealthCare’s $945 million Sofie Biosciences acquisition could deepen its precision-imaging strate…
Qiagen Shares Gain as Strategic-Buyer Talks Raise M&A Speculation
Qiagen shares gained after a report said talks with a strategic buyer had advanced, reviving questio…
Pancreatic Cancer Drug Approval Could Lift Oncology Biotech Sentiment
An FDA approval for metastatic pancreatic cancer may improve sentiment across oncology biotech, thou…
AbbVie’s JUVMO Approval Opens New Parkinson’s Growth Opportunity for Investors
AbbVie’s FDA approval of JUVMO may expand its neurology pipeline and offer a potential diversificati…
Spyre Therapeutics Insiders Sell More Than $3.6 Million in SYRE Stock Despite Bullish Analyst Coverage
Spyre insiders sold more than $3.6 million in SYRE stock as JPMorgan and Baird maintained bullish vi…
MRNA’s Nasdaq-100 Inclusion Draws Retail Attention to SLS and IBRX
Moderna’s Nasdaq-100 inclusion may increase index-related attention, while retail traders compare sm…
AbbVie Wins FDA Approval for JUVMO Parkinson’s Therapy: What ABBV Investors Should Watch
AbbVie’s FDA approval of JUVMO adds a Parkinson’s therapy to its neuroscience portfolio, but commerc…
Needham’s Buy Rating Puts LB Pharmaceuticals’ 2027 Trial Catalyst in the Spotlight
Needham’s Buy initiation highlights LB Pharmaceuticals ahead of the pivotal NOVA-2 schizophrenia rea…
Pfizer’s Tilrekimig Advances to Phase 3 as Investors Seek New Growth Drivers
Pfizer’s tilrekimig met its Phase 2 goal and is advancing to Phase 3, but the program remains an opp…